<DOC>
	<DOCNO>NCT00171847</DOCNO>
	<brief_summary>Phase IV trial investigate effect combination Letrozole trastuzumab metastatic breast cancer patient</brief_summary>
	<brief_title>Study Efficacy Safety Letrozole Combined With Trastuzumab Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Postmenopausal Her2 overexpression ER and/or PgR positive Metastatic Breast Cancer Previous treatment trastuzumab Significant Liver renal impairment Erbb2 negative and/or ER PgR negative Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Letrozole</keyword>
</DOC>